Market Price

36.60 

1.20 3.4%

as of May 16 '22

52 Week Range:

31.80 72.00


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. The company markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation has a collaboration agreement with D. Western Therapeutics Institute for the development of novel intraocular products for the treatment of glaucoma. The company was founded in 1998 and is headquartered in San Clemente, California.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Equity (BVPS) 2.70
3.07
3.20
3.96
3.91
11.93
11.27
growth rate 13.7% 4.2% 23.8% -1.3% 205.1% -5.5%
Earnings BIT -13.17
-10.30
4.24
3.04
-13.00
-18.02
-98.84
growth rate 0.0% 100.0% -28.3% -100.0% 0.0% 0.0%
Avg.PE 755.09
362.81
-819.16
-819.16
-819.16
-819.16
-819.16
growth rate -52.0% -100.0% 0.0% 0.0% 0.0% 0.0%
ROA -40.93
-42.62
-52.20
3.60
-0.06
-6.95
3.01
-13.20
-4.83
growth rate 0.0% 0.0% 100.0% -100.0% 0.0% 100.0% -100.0% 0.0%
ROE 4.26
-0.07
-8.30
3.64
-17.95
-7.91
growth rate -100.0% 0.0% 100.0% -100.0% 0.0%
ROIC 3.99
-1.14
-9.35
3.02
-13.02
-4.27
growth rate -100.0% 0.0% 100.0% -100.0% 0.0%
Cur. Ratio 2.19
0.52
5.11
7.09
5.58
5.81
4.56
9.45
7.67
growth rate -76.3% 882.7% 38.8% -21.3% 4.1% -21.5% 107.2% -18.8%
Quick Ratio 1.76
0.38
4.85
6.50
5.06
5.24
3.68
8.86
7.06
growth rate -78.4% 1,176.3% 34.0% -22.2% 3.6% -29.8% 140.8% -20.3%
Leverage 1.23
1.15
1.20
1.19
1.22
1.51
1.79
growth rate -6.5% 4.4% -0.8% 2.5% 23.8% 18.5%
Balance Sheet Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Acct.Receivable 5.40
7.55
14.31
16.66
18.67
38.42
36.06
growth rate 39.9% 89.5% 16.4% 12.1% 105.7% -6.1%
Acct.Payable 3.30
3.63
2.97
6.24
6.29
5.78
4.37
growth rate 10.0% -18.2% 110.5% 0.7% -8.0% -24.4%
Cur.Assets 10.55
104.14
120.02
149.46
176.57
262.88
469.44
growth rate 886.7% 15.3% 24.5% 18.1% 48.9% 78.6%
Total Assets 26.02
116.66
134.37
165.84
206.97
818.40
1,005.50
growth rate 348.3% 15.2% 23.4% 24.8% 295.4% 22.9%
Cash 2.30
21.57
6.49
24.51
29.82
62.43
96.60
growth rate 836.3% -69.9% 277.4% 21.7% 109.4% 54.7%
Inventory 2.26
4.10
6.84
11.22
13.28
42.58
15.81
growth rate 81.4% 67.1% 64.0% 18.4% 220.6% -62.9%
Cur.Liabilities 20.19
20.36
16.94
26.79
30.37
57.70
49.70
growth rate 0.9% -16.8% 58.2% 13.4% 90.0% -13.9%
Liabilities 29.17
21.37
17.10
27.63
33.11
145.13
338.05
growth rate -26.8% -20.0% 61.6% 19.8% 338.3% 132.9%
LT Debt 8.97
0.77
189.42
growth rate -91.5% 201.1%
Equity -151.30
95.19
117.27
138.20
173.86
673.27
667.45
growth rate 100.0% 23.2% 17.9% 25.8% 287.3% -0.9%
Common Shares 25.00
25.00
17.00
36.00
34.00
35.00
41.00
44.00
46.00
growth rate 0.0% -32.0% 111.8% -5.6% 2.9% 17.1% 7.3% 4.6%
Cash Flow Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Capital Expenditures 0.87
0.88
6.28
6.31
10.32
4.72
6.94
growth rate 1.0% 615.9% 0.5% 63.4% -54.2% 46.8%
Cash From OA -7.11
-2.19
12.31
26.09
18.86
-0.37
-22.99
growth rate 0.0% 100.0% 112.0% -27.7% -100.0% 0.0%
FCF per Share -0.11
0.10
0.25
0.23
0.24
-0.76
-0.01
growth rate 100.0% 150.0% -8.0% 4.4% -100.0% 0.0%
Sale Purchase of Stock 1.65
116.91
8.05
4.67
growth rate 6,985.6% -93.1% -42.1%
FCF -14.00
-8.00
-3.00
6.00
19.00
9.00
-5.00
-30.00
-23.00
growth rate 0.0% 0.0% 100.0% 216.7% -52.6% -100.0% 0.0% 0.0%
Income Statement Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21
Sales 45.59
71.70
114.40
159.25
181.28
236.98
224.96
growth rate 57.3% 59.6% 39.2% 13.8% 30.7% -5.1%
Op.Income -13.17
-10.30
4.24
3.04
-13.00
-18.02
-98.84
growth rate 0.0% 100.0% -28.3% -100.0% 0.0% 0.0%
IBT -14.04
-38.29
4.57
0.00
-12.37
-50.04
-132.31
growth rate 0.0% 100.0% -100.0% -100.0% 0.0% 0.0%
Net Income -12.13
-37.24
4.52
-0.09
-12.95
15.42
-120.35
growth rate 0.0% 100.0% -100.0% 0.0% 100.0% -100.0%
EPS -0.51
-0.49
-2.13
0.12
-0.37
0.37
-2.70
-1.07
growth rate 0.0% 0.0% 100.0% -100.0% 100.0% -100.0% 0.0%
Gross Profit 34.17
58.71
98.22
138.20
156.20
202.42
157.95
growth rate 71.8% 67.3% 40.7% 13.0% 29.6% -22.0%
R&D 19.21
25.05
29.22
38.91
49.68
67.78
84.44
growth rate 30.4% 16.7% 33.1% 27.7% 36.4% 24.6%

Quarterly Statements

Item Name Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Earnings BIT -8.85
-21.08
-11.81
-9.22
-13.98
growth rate 0.0% 0.0% 0.0% 0.0%
Balance Sheet Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Acct.Receivable 32.89
36.06
36.69
37.57
35.24
growth rate 9.7% 1.8% 2.4% -6.2%
Acct.Payable 6.77
4.37
8.62
6.96
8.46
growth rate -35.5% 97.3% -19.3% 21.6%
Cur.Assets 454.45
469.44
474.30
490.54
501.81
growth rate 3.3% 1.0% 3.4% 2.3%
Total Assets 994.51
1,005.50
1,022.78
1,043.73
1,064.13
growth rate 1.1% 1.7% 2.1% 2.0%
Cash 80.99
96.60
96.63
118.30
113.13
growth rate 19.3% 0.0% 22.4% -4.4%
Inventory 19.89
15.81
15.27
17.50
19.72
growth rate -20.5% -3.4% 14.6% 12.7%
Cur.Liabilities 46.69
49.70
335.56
349.48
63.45
growth rate 6.4% 575.2% 4.2% -81.8%
Liabilities 332.95
338.05
433.00
459.40
463.08
growth rate 1.5% 28.1% 6.1% 0.8%
LT Debt 186.68
189.42
279.68
growth rate 1.5% 13.9%
Equity 661.56
667.45
589.77
584.33
601.05
growth rate 0.9% -11.6% -0.9% 2.9%
Common Shares 0.05
0.05
0.05
0.05
0.05
growth rate 0.0% 2.2% 0.0% 2.2%
Cash Flow Statement Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Capital Expenditures 1.28
2.15
17.18
11.36
9.92
growth rate 67.5% 701.0% -33.9% -12.7%
Cash From OA -9.57
10.60
4.18
7.39
17.79
growth rate 100.0% -60.6% 76.9% 140.7%
Sale Purchase of Stock
growth rate
FCF -10.85
8.46
-13.00
-3.97
7.87
growth rate 100.0% -100.0% 0.0% 100.0%
Income Statement Sep '20 Dec '20 Mar '21 Jun '21 Sep '21
Sales 64.83
73.23
67.97
78.09
74.71
growth rate 13.0% -7.2% 14.9% -4.3%
Op.Income -8.85
-21.08
-11.81
-9.22
-13.98
growth rate 0.0% 0.0% 0.0% 0.0%
IBT -16.64
-13.89
-16.19
-17.27
6.43
growth rate 0.0% 0.0% 0.0% 100.0%
Net Income -15.75
-10.65
-16.47
-17.48
6.23
growth rate 0.0% 0.0% 0.0% 100.0%
Gross Profit 49.80
52.76
51.34
60.33
59.34
growth rate 5.9% -2.7% 17.5% -1.7%
R&D 20.10
22.59
21.22
24.26
28.85
growth rate 12.4% -6.1% 14.3% 18.9%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (5.15)

YOY Growth Grade:

F (15.91)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

Current EPS is negative, therefore value price cannot be calculated.

PE and EPS

Historical Current Forward
PE -819.16 -92.66
EPS / Growth -0.40

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 50.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 40.0% 50.0% 61.0%
Future PE 0.01 0.01 40.69
Future EPS 0.00 0.00 0.00
Value Price
MOS %
0.00
-100.0%
0.00
-100.0%
0.00
-100.0%
MOS Price 0.00 0.00 0.00
IRT 99.00 99.00 99.00

Graham Number:

Current EPS is negative, therefore Graham Number cannot be calculated.
NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.